Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492712 | 0.93 | CYP11B2 (0.51) | CYP11B2HSD11B1TSHR | |
| SCHEMBL13339990 | 0.93 | CYP11B2 (0.51) | CYP11B2HSD11B1TSHR | |
| SCHEMBL3491293 | 0.88 | CYP11B2 (0.48) | CYP11B2HSD11B1TSHRHTR2CCYP1A2 | |
| SCHEMBL3491295 | 0.85 | CYP11B2 (0.48) | CYP11B2HSD11B1TSHRHTR2CKDM4C | |
| SCHEMBL3494303 | 0.81 | CYP11B2 (0.49) | CYP11B2HSD11B1MEN1KMT2A | |
| SCHEMBL13819262 | 0.80 | CYP11B2 (0.39) | CYP11B2MEN1KMT2ACNR1 | |
| SCHEMBL3491411 | 0.78 | CYP11B2 (0.49) | CYP11B2TSHRKDM4CMEN1KMT2A | |
| SCHEMBL3494801 | 0.78 | CYP11B2 (0.55) | CYP11B2TSHRKDM4CCNR1 | |
| SCHEMBL3491294 | 0.77 | CNR1 (0.42) | HSD11B1TSHRHTR2CHTTHPGD | |
| SCHEMBL2822478 | 0.77 | CYP11B2 (0.49) | CYP11B2HSD11B1TSHRHTR2CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CYP11B2 29/4885HSD11B1 103/4885TSHR 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.